Introduction: A Smarter Approach to Prostate Cancer Screening
Prostate cancer screening has long relied on the prostate-specific antigen (PSA) test. This is a simple blood test used by doctors worldwide, including at our private GP surgery in Fulham. However, while PSA testing is widely available, it has its flaws. It can often lead to unnecessary biopsies and anxiety.
Thankfully, advanced screening methods such as the Stockholm3 test (STHLM3) are revolutionising prostate cancer detection. the Stockholm3 might sound like a 90s Indie band. However, it offers higher accuracy and fewer unnecessary procedures in patients with elevated PSA.
If you’re considering prostate cancer screening in London, here’s what you need to know about the latest innovations.
The PSA Test: A Good but Imperfect Tool
The PSA test measures prostate-specific antigen levels in the blood, helping detect potential prostate issues. However, elevated PSA levels don’t necessarily indicate cancer. Benign prostate enlargement, infections, or inflammation can also cause an increase.
This low specificity often leads to unnecessary MRI scans and biopsies, causing undue stress for patients. At our Fulham GP clinic, we focus on providing cutting-edge screening options that minimise unnecessary interventions.
Stockholm3 Test: A Game-Changer in Prostate Cancer Screening
The Stockholm3 test (STHLM3) is an innovative approach that combines:
✅ Biomarkers (blood-based indicators of prostate health)
✅ Genetic testing (to assess hereditary cancer risks)
✅ Clinical data (age, family history, and other risk factors)
How Does Stockholm3 Improve Prostate Cancer Diagnosis?
A major study found that Stockholm3 reduced the need for prostate biopsies by 32% while maintaining high accuracy in detecting aggressive cancers.
The National Institute for Health and Care Excellence (NICE) has also acknowledged Stockholm3’s potential to improve prostate cancer screening, helping reduce unnecessary MRI scans and biopsies.
Reflex Testing: Enhancing PSA Results with Greater Accuracy
At our Fulham private GP clinic, we understand the importance of precision in diagnostics. The Stockholm3 test acts as a reflex test, meaning:
- If PSA levels are elevated, Stockholm3 analyzes additional risk factors to determine whether a biopsy is truly needed.
- This prevents unnecessary biopsies while still identifying high-risk patients.
By integrating Stockholm3 testing into our private GP services in London, we offer a more tailored, patient-friendly approach to prostate cancer screening.
Stockholm3’s Global Success: A Reliable Test for All Ethnicities
One concern with many prostate cancer screening tests is their effectiveness across different ethnic groups. The SEPTA trial, conducted in North America, confirmed that Stockholm3 is highly accurate across diverse populations, showing:
- Better specificity (fewer false positives)
- Non-inferior sensitivity (still detects all significant cancers)
This is a crucial breakthrough, as ethnicity is a known risk factor for prostate cancer. At our private GP clinic in London, we strive to provide the best screening options for all patients.
The Future of Prostate Cancer Screening in London
Advancements like Stockholm3 represent a major step forward in prostate cancer detection. As we move toward a more personalised, risk-based approach, our clinic is committed to offering the most advanced screening technologies available.
If you’re considering prostate cancer screening in Fulham, our expert private GPs provide:
✅ Comprehensive prostate health assessments
✅ Advanced genetic testing
✅ Cutting-edge screening methods
Book a Prostate Cancer Screening with a Private GP in Fulham
Early detection saves lives, but screening should be accurate and stress-free. At our London private GP surgery, we offer advanced prostate cancer screening that helps you avoid unnecessary biopsies while ensuring your health remains a top priority.
🔹 Contact us today to book a prostate health consultation at our Fulham GP clinic.
DR LUCY HOOPER
MB BS BSc MRCGP MA DRCOG DCH
Lucy is a GP and co-founder of Coyne Medical. She graduated with honours from Imperial College London, trained at St Mary’s Hospital, and holds a Master’s in Medical Ethics and Law. Her clinical interests span women’s health, preventive medicine, and genomics, with a particular focus on using advanced biomarkers to build a more complete picture of long-term health.
British Society for Genetic Medicine · European Atherosclerosis Society ·
Independent Doctors Federation
As seen in BBC, The Guardian, Women’s Health, The Times and Tatler
For educational purposes. This article is written by a practising GP and is intended to inform, not replace a consultation with your own doctor. It does not constitute medical advice. A note on clinical guidelines: Coyne Medical is an independent private clinic. Our approach is guided by the best available evidence, tailored to each individual. This may go beyond standard NHS or NICE guidance, which is designed for population-level care and weighted by resource constraints.
